BOSTON--()--®, the trailblazer in AI-powered neural sensors for cognitive health, wellness, and gesture control, today announced an equity investment from Samsung Venture Investment Corporation (Samsung Ventures). This investment highlights the dedication of Samsung Ventures to advancing future healthcare technology and acknowledges Pison’s potential in neurocognitive assessment and tracking capabilities.

Pison was founded in 2016 with funding from the Massachusetts Institute of Technology, National Science Foundation, and the ALS Association. The company has also received funding from several Small Business Innovation Research (SBIR) awards from the U.S. Department of Defense, and various research institutions. In addition, the FY2025 National Defense Authorization Act (NDAA) highlights the value of neural biosensors for advancing warfighter health and readiness, namely detecting traumatic brain injuries and tracking chronic fatigue.
Pison’s innovative sensor technology detects brain activity from three nerve bundles in the wrist. Using both active and passive AI algorithms, it extracts neurocognitive data, providing insights into mental acuity and impairment from poor sleep, chronic fatigue, anxiety, neurodegenerative conditions, drugs, alcohol, and subconcussive brain injuries.
“We’re honored to have Samsung Venture Investment Corporation involved in this funding journey for Pison, as their support offers vital resources to bring forward transformative solutions with meaningful societal impact,” said John Croteau, CEO of Pison. “Our mobile apps and subscription services aim to redefine cognitive performance and productivity—whether at home, on the athletic field, in the workplace, or within mission-critical job functions.”

**About Samsung Venture Investment Corporation**
Founded in 1999, Samsung Venture Investment is the corporate venture capital arm of Samsung Electronics based in Seoul, South Korea. The firm prefers to invest in companies operating in semiconductors, telecommunication, software, internet, bioengineering, and medical sectors across Europe, Asia, and North America.

**About Pison Technology**
is advancing the frontier of human potential with the world’s first AI-powered, neural sensing platform. Patented, non-invasive electroneurography (ENG) algorithms and the introduction of a new sensor array create life-changing applications in cognitive performance, disease diagnostics and management, and quality of life. Pison was founded in 2016 with funding from the Massachusetts Institute of Technology, National Science Foundation, and the ALS Association to help patients with neurodegenerative disorders better navigate a world made smaller by their diseases. By harnessing the power of the mind in real-time, users gain access to better health and higher achievement in every domain while reaching peak mental and physical performance on the playing field, at work, and in everyday life.

Pison Announces Investment from Samsung Ventures, Strengthening Strategic Presence in Consumer Wearables for Neurocognitive Performance

Pison, a company specializing in AI-powered neural sensors for cognitive health, announced an equity investment from Samsung Venture Investment Corporation (Samsung Ventures). This investment underscores Samsung Ventures' commitment to advancing healthcare technology and highlights Pison's potential in neurocognitive assessment and tracking. Pison was founded in 2016 with funding from MIT, NSF, and the ALS Association, among others, and has received various SBIR awards and research funding. Pison's technology detects brain activity from nerve bundles in the wrist, extracting neurocognitive data for insights into mental health.